IsoAid Wins Three-Year Brachytherapy Contract From Amerinet
Posted on: Friday, 19 September 2008, 12:00 CDT
IsoAid, a provider of brachytherapy products, and Amerinet, a healthcare group purchasing organization, have announced that IsoAid has been awarded a three-year brachytherapy contract to provide Amerinet members with a complete line of brachytherapy products used primarily in the treatment of prostate cancer.
The agreement will begin on October 1, 2008 and run for a three-year term. The agreement is said to offer Amerinet's membership competitive market pricing, and access to IsoAid's Advantage I-125 and Advantage Pd-103 seeds and related brachytherapy products.
Source: Datamonitor
Related Articles
- Amerinet Selects IsoAid to Provide Membership With Prostate Brachytherapy Products Under a Three-Year Agreement
- Amerinet and McKesson Sign Exclusive Multi-Product Agreement
- IsoRay Medical, Inc., Set to Transfer Production of Proxcelan(TM) (Cesium-131) Brachytherapy Seeds to New Expanded Facilities in Richland
- Premier Selects Oncura(TM) to Provide Membership With Exclusive Prostate Brachytherapy Products Under New Three-Year Agreement
- HealthTrust Purchasing Group Selects ONCURA(TM) to Provide Membership With Prostate Brachytherapy Products Under a New Three-Year Agreement
- North American Scientific Announces FDA Clearance of Low-Dose Breast Brachytherapy Product
- Amerinet Contracts With MEDRAD for Full Line of MR, CT and Cardiovascular Products
- Theragenics Corporation(R) Secures Agreement With MedAssets; Company Will Distribute Both TheraSeed(R) and I-Seed to GPO Members
- Amerinet Selects ONCURA(TM) to Provide Membership With Prostate Brachytherapy Products Under a New Three-Year Agreement
Rating: 2.6 / 5 (10 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds